Invent-Life Science

We’re proud to share the successful completion of our hands-on library preparation training at University of Dhaka! 🎓🧬

Participants gained practical experience in Illumina DNA Prep, strengthening their skills in modern sequencing workflows.

👏 Congratulations to all the trainees for their dedication and enthusiasm throughout the program.

🌟 Wishing them all the very best for their future endeavors in research and innovation!

🧠 For Neuro-Oncology & Molecular Pathology Professionals,

We are pleased to highlight the Pillar oncoReveal™ Multi-Cancer CNV + RNA Fusion Panel, now available at TMSS Biomolecular Lab.

This comprehensive genomic profiling solution is designed to support glioma management and broader oncology practice, delivering integrated DNA and RNA analysis in a single workflow.

🔬 Key Features:

· 60 DNA genes – covering critical alterations including IDH1/2, EGFR, BRAF, TERT, CDKN2A/B, and more
· 18 RNA genes – enabling robust detection of fusions and structural variants, including FGFR, NTRK, ROS1, MET, and KIAA1549–BRAF
· CNV + fusion detection in one assay, maximizing diagnostic yield and therapeutic matching

📌 Why This Matters:

· Streamlines diagnostic workup for gliomas, supporting integrated histomolecular classification
· Facilitates identification of FDA-approved and guideline-recommended targeted therapy opportunities
· Consolidates testing to reduce turnaround time and tissue requirements

TMSS Biomolecular Lab
Thengamara, Rangpur Road, Bogura
📞 +8801733352094
📧 [email protected]
🔗 www.tmssbiomolecularlab.com

🧠 Glioma doesn't wait — neither should your diagnosis.

TMSS Biomolecular Lab now offers comprehensive glioma molecular profiling using the Pillar oncoReveal™ CNV + RNA Fusion Panel — covering IDH1/2, EGFR, BRAF, NTRK, EGFRvIII, FGFR3 fusions & more in a single test.

Covered DNA Genes
Our DNA panel analyzes critical mutations and copy number variations (CNVs) to stratify adult and pediatric gliomas:
​
IDH1 and IDH2: Essential for classifying adult diffuse gliomas, including astrocytomas and oligodendrogliomas.
​
TP53 and PTEN: Key prognostic and diagnostic markers in high-grade astrocytomas.
​
EGFR: Detects critical point mutations and driving gene amplifications.
​
BRAF: Identifies V600E mutations crucial for pediatric gliomas and pleomorphic xanthoastrocytoma.
​
PDGFRA: Highlights copy number gains and driving variations.
​
PIK3CA and PIK3R1: Assesses critical PI3K pathway alterations.
​

Covered RNA Fusions
Our RNA panel identifies structural variants and splice events driving distinct glioma subtypes:
​
EGFRvIII: Specific detection of the most common glioblastoma splice variant.
​
BRAF: Identifies fusions like KIAA1549-BRAF to confirm pilocytic astrocytomas.
​
FGFR3: Detects FGFR3-TACC3 fusions to identify targetable glioblastoma subsets.
​
NTRK1, NTRK2, and NTRK3: Broad fusion coverage to qualify patients for TRK inhibitor therapies.

MET: Assesses exon 14 skipping and fusion events.

🔬 One sample. Complete WHO-compliant answers.
📍 Bogura, Bangladesh
🌐 tmssbiomolecularlab.com